Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARAMEL: Carfilzomib and Melphalan Conditioning for ASCT in Multiple Myeloma
NCT01842308Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Jun 2013
- Primary completion
- Oct 2017
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib in multiple myeloma (MM), sponsored by Mayo Clinic. Started Jun 2013; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01842308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01842308.